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Many respiratory diseases, but this is also 
true for other diseases, including asthma 
and chronic obstructive pulmonary dis-
ease  (COPD),  should  be  more  properly 
defined as syndromes as they are charac-
terized by a high degree of heterogeneity. 
This heterogeneity is largely responsible for 
the variability in drug response. A strik-
ing example is COPD where patients with 
chronic bronchitis or emphysema who are 
completely  different  are  classified  under 
the same nosographic entity, principally 
on the basis of functional characteristics. 
Pharmacological response in so different 
clinical and pathological phenotypes can 
be very variable even when the same drug, 
at the same dose, for the same duration of 
treatment is administered. This can make 
it difficult the interpretation of clinical tri-
als in patients with COPD. Identification 
of patients who are more likely to respond 
to pharmacological treatment can increase 
the  risk/benefit  ratio  in  the  individual 
patients  and  reduce  health  care  costs. 
A  promising  example  is  the  association 
between leukotriene receptor antagonists 
(LTRA) response in patients with asthma 
and genetic polymorphisms of the leuko-
triene pathway and/or receptors. A priori 
identification of LTRA responders among 
patients  with  asthma,  that  is  currently 
based on a therapeutic trial, would enable 
to exploit the therapeutic effects of this 
class of drugs in the responders, avoiding 
exposure of non-responders to unjustifi-
able side effects and costs. More generally, 
a personalized pharmacotherapy of respi-
ratory  diseases  would  improve  manage-
ment of the individual patients, in terms 
of greater efficacy and safety, and reduce 
the health care costs. Personalized pharma-
cotherapy requires the implementation of 
more  sophisticated  diagnostic  tools  that 
should be based on a better understanding 
of the pathophysiology of respiratory dis-
eases and the development of sensitive and 
validated non-invasive techniques. There is 
no doubt that chronic airway   inflammation 
has  a  pivotal  pathophysiological  role  in 
asthma.  The  most  convincing  evidence 
for that is the fact that anti-inflammatory 
drugs such as inhaled glucocorticoids are 
the most effective long-term treatment for 
asthma control. COPD is also character-
ized by lung inflammation, but the effi-
cacy of glucocorticoids in this disease is 
much lesser than in asthma indicating a 
different type of inflammation, relatively 
resistant to these drugs. At present, assess-
ment  of  airway  inflammation  is  mainly 
based  on  invasive  techniques  including 
bronchoscopy and bronchial biopsies that 
cannot be used routinely or conventional 
diagnostic  procedures  including  clinical 
assessment,  pulmonary  function  test-
ing, bronchial challenge tests, and patient 
reported outcomes that are indirect meas-
ures of inflammation and/or lack sensitiv-
ity. In patients with asthma, measurement 
of fractional exhaled nitric oxide (FENO) is 
a standardized, validated and well-accepted 
non-invasive surrogate marker of airway 
inflammation.  FENO  analyzers  provide 
immediate results and are cleared by the US 
Food and Drugs Administration for assess-
ing airway inflammation and monitoring 
therapy in patients with asthma. Compared 
with asthma control based on conventional 
outcomes, asthma control based on FENO 
measurement enables a reduction of daily 
doses of inhaled glucocorticoids of about 
40%  with  similar  efficacy  and  reduced 
costs  and,  likely,  side  effects.  Although 
the clinical utility of this technique is still 
debated, many clinical trials on antiasth-
matic pharmacological treatment include 
FENO among the outcome measures due 
to the importance of assessing drug effects 
based on their mechanisms of action, e.g., 
the  effects  of  anti-inflammatory  drugs 
on  surrogate  markers  of  inflammation. 
Analysis of eosinophil counts in induced 
sputum  is  a  direct  measure  of  airway 
inflammation that can be used for identify-
ing phenotypes of patients with asthma and 
COPD and predicting response to inhaled 
  glucocorticoids. However, this technique is 
difficult to be used routinely as it is semi-
invasive, is not well-accepted to patients, 
requires specialized staff and facilities, and 
is unfeasible in children. Advances in our 
understanding of the clinical pharmacol-
ogy of drugs for respiratory diseases should 
be attainable using measurements of vali-
dated biomarkers. Measurement of FENO 
was a major breakthrough in patients with 
asthma and a relevant example of a surro-
gate marker of airway inflammation that 
translated effectively from basic research, 
through validation and standardization of 
the technique, to clinical setting. However, 
FENO is only one surrogate marker of air-
way inflammation, useful in patients with 
asthma, particularly those with airway eosi-
nophilia, but unlikely to reflect the whole 
complexity of the inflammatory process in 
respiratory diseases and its multiple expres-
sions within a given   disease/syndrome. To 
better understand the pathophysiology of 
respiratory diseases, and its phenotypes, 
a  molecular  approach  to  the  individual 
patients  based  on  omics  technologies  is 
being  implemented.  These  technologies 
include  genomics,  transcriptomics,  pro-
teomics,  lipidomics,  metabolomics,  and 
brethomics, a new omics technology that 
aims at identifying and quantifying breath 
biomolecules by reference analytical tech-
niques  and  identifying  selective  profiles 
of breath volatile organic compounds by 
electronic nose, a chemical sensor array. 
Omics  technologies,  that  require  close 
interdisciplinary  interactions  (bioengi-
neering, biophysics, bioinformatics), could 
have important implications for the phar-
macological treatment of respiratory dis-
eases: (1) identification of subphenotypes 
of patients with respiratory diseases that 
would facilitate the implementation of a 
tailored, personalized, pharmacotherapy; 
(2) unraveling novel potential targets for 
pharmacological intervention and devel-
opment of new drugs; (3) a better under-
standing of the mechanism(s) of action of Frontiers in Pharmacology  |  Pharmacotherapy of Respiratory Diseases    November 2010  | Volume 1  | Article 131  |  2
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and costs. This requires a focus on the indi-
vidual patient, interdisciplinary work, and 
good, independent, research.
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nue to a personalized   pharmacotherapy. This 
requires a “handprint” for each single patient 
that should be based on the combination of 
conventional and novel techniques for the 
diagnosis and monitoring of pharmacologi-
cal therapy and robust systems biology for 
data analysis. Systems biology is also required 
for an unbiased approach to discovery of new 
biomarkers and/or pharmacological targets, 
which in turn might improve characteriza-
tion of patients and their treatment.
One of the major challenges in respira-
tory medicine is the identification of a per-
sonalized, tailored, pharmacotherapy that 
would optimize efficacy, tolerability, safety, 
currently available drugs that would result 
in a more rational use of these drugs and 
could suggest new pharmacological strate-
gies; (4) the evidence of ongoing pulmo-
nary  inflammation  in  patients  with  no 
symptoms and maintained lung function 
that might require starting pharmacologi-
cal therapy.
Randomized clinical trials are still the best 
tool for assessing the pharmacological pro-
files of existing and new drugs, but their con-
clusions apply to large patient populations. 
The evidence of a large variability in drug 
response raises the issue of the best treatment 
for the individual patient and paves the ave-